Holistic and Multidisciplinary Approaches to Multiple Myeloma Management
Closing out their program on multiple myeloma, expert panelists consider the role of holistic and multidisciplinary care when managing patients within the current paradigm.
Read More
Impact of Clinical Trials on the Management of Multiple Myeloma
Continuing its discussion on clinical trials in multiple myeloma, the panel emphasizes the impact that data may have on the real-world treatment landscape.
Read More
Importance of Clinical Trial Enrollment in Multiple Myeloma
Key opinion leaders in multiple myeloma management elucidate the value of clinical trials and share enthusiasm for improving enrollment when possible.
Read More
Multiple Myeloma: Regulatory Aspects of Treatment Development and Approval
A focused discussion on the regulatory aspects of drug testing and approval, globally, with respect to the setting of multiple myeloma management.
Read More
Educating Patients on Treatment Options for Multiple Myeloma
Expert panelists consider best methods in educating patients on their options for therapy following a diagnosis of multiple myeloma.
Read More
Treatment for Newly Diagnosed Multiple Myeloma: Addressing Disparities in Care
Comprehensive insight to disparities that may impact a patient’s access to therapy for multiple myeloma and how these may be overcome.
Read More
Treatment Considerations for Patients with Newly Diagnosed Multiple Myeloma
Panelists share a brief discussion on the current treatment armamentarium available to patients with newly diagnosed multiple myeloma.
Read More
Role of Diagnostic Testing in Patients with Multiple Myeloma
Experts in multiple myeloma management consider essential tests that aid in the diagnosis and treatment of newly presenting patients.
Read More
Educating on Multiple Myeloma: Patient and Physician Resources
Shared insight from key opinion leaders on educational resources made available to physicians and patients, respectively, regarding multiple myeloma management.
Read More
Multiple Myeloma: Challenges in Diagnosis and Role of Multidisciplinary Care
Opening its discussion on key unmet needs in multiple myeloma management, a panel of experts discuss key challenges faced when diagnosing patients with multiple myeloma and review the impact of having a multidisciplinary care team.
Read More
Investigational Agents for Relapsed/Refractory Myeloma
Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
Read More
CARTITUDE-1 and CARTITUDE-2 Trials in Multiple Myeloma
Multiple myeloma experts evaluate the safety and efficacy of ciltacabtagene autoleucel for RRMM, as seen in updated data presented at ASCO 2021 for the CARTITUDE-1 and CARTITUDE-2 studies.
Read More
Using CAR T Therapy for Relapsed/Refractory Myeloma
Nina Shah, MD, leads the discussion on the role of CAR T-cell therapy, including idecabtagene vicleucel, for the management of RRMM.
Read More
Role of BCMA-Targeted Agents in Myeloma
Experts in multiple myeloma review the use of belantamab mafodotin as described in the DREAMM-2 trial and discuss the management of the associated ototoxicity.
Read More
Treatment of Relapsed/Refractory Myeloma: Novel Agents
Cristina Gasparetto, MD; Sagar Lonial, MD, FACP; Joseph Mikhael, MD; and Nina Shah, MD, discuss emerging agents available for the treatment of RRMM.
Read More
PI-Based Combinations for Relapsed Myeloma
A review of data from key clinical trials, including CANDOR and IKEMA, for relapsed/refractory multiple myeloma.
Read More
CASSIOPEIA Trial of Dara-VTd in Transplant-Eligible Myeloma
Joseph Mikhael, MD, reviews updated results presented at the 2021 ASCO annual meeting of the phase 3 CASSIOPEIA trial for NDMM, and Nina Shah, MD, comments on how the data may inform the addition of daratumumab to triplet therapy at relapse.
Read More
Using IMiD-Based Strategies for Relapsed Myeloma
Multiple myeloma experts discuss the role of pomalidomide-containing regimens for the treatment of RRMM.
Read More
Approaching Treatment of Relapsed/Refractory Myeloma
Factors to consider when approaching therapy selection for patients with multiple myeloma disease progression.
Read More
Role of MRD Assessment in Myeloma
Cristina Gasparetto, MD, leads the discussion on whether MRD testing can influence treatment decisions for newly diagnosed multiple myeloma.
Read More
Improving Maintenance Therapy for Myeloma
Multiple myeloma experts share their thoughts on improving on currently available maintenance therapy, particularly for high-risk patients, and review their personal approaches to maintenance therapy for standard- and high-risk disease.
Read More
High-Risk Multiple Myeloma: Selecting Initial Therapy
Sagar Lonial, MD, FACP, leads the discussion on selecting the optimal proteasome inhibitor, bortezomib or carfilzomib, for patients with high-risk multiple myeloma.
Read More
Standard Induction for Newly Diagnosed Symptomatic Myeloma
Experts in multiple myeloma comment on standard induction therapy for patients with newly diagnosed symptomatic myeloma and consider recommended triplet regimens.
Read More
Overview of Newly Diagnosed Multiple Myeloma
Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, discuss the diagnostic work-up for a patient with newly diagnosed multiple myeloma and the impact of age and frailty scores on transplant eligibility.
Read More